Purpose. Autophagy is a cell survival mechanism that plays a critical role in pancreatic carcinogenesis. Murine studies have previously demonstrated that treatment with the late-autophagy inhibitor chloroquine in combination with chemotherapy limited tumor growth. Methods. In this phase 1/2 trial, we examined treatment with hydroxychloroquine (HCQ) and gemcitabine for patients with pancreatic adenocarcinoma. The primary endpoints were safety and tolerability, evaluated by Storer's dose escalation design. Secondary endpoints were CA 19-9 biomarker response, R0 resection rates, survival, and correlative studies of autophagy. Results. Thirty-five patients were enrolled. There were no dose-limiting toxicities and no grade 4/5 events related to treatment. Nineteen patients (61 %) had a decrease in CA 19-9 after treatment. Twenty-nine patients (94 %) underwent surgical resection as scheduled, with a 77 % R0 resection rate. Median overall survival was 34.8 months (95 % confidence interval, 11.57 to not reached). Patients who had more than a 51 % increase in the autophagy marker LC3-II in circulating peripheral blood mononuclear cells had improvement in disease-free survival (15.03 vs. 6.9 months, p \ 0.05) and overall survival (34.83 vs. 10.83 months, p \ 0.05). No outcome differences were demonstrated in the 81 % of patients with abnormal p53 expression assessed by immunohistochemistry in the resected specimens. Conclusions. Preoperative autophagy inhibition with HCQ plus gemcitabine is safe and well tolerated. Surrogate biomarker responses (CA 19-9) and surgical oncologic outcomes were encouraging. p53 status was not associated with adverse outcomes.
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Autophagy is a pathway of cell survival in response to stress in which damaged organelles, proteins, and materials are recycled to enhance energy production. [1] [2] [3] Autophagy is crucial to late pancreatic carcinogenesis, allowing cancer cells to survive nutrient deprivation, hypoxia and treatment with chemotherapy, leading to chemoresistance. [4] [5] [6] [7] [8] [9] [10] [11] Levels of autophagy have been linked to prognosis in pancreatic ductal adenocarcinoma (PDA). 12 Inhibition of autophagy results in increased apoptosis and therefore represents a potential mechanism to induce cell death in established PDA.
Hydroxychloroquine (HCQ) is an inexpensive drug that blocks acidification of the lysosome, inhibiting the final step of autophagy.
14 Although originally developed to treat patients with malaria, HCQ has been utilized for treatment of systemic lupus erythematosus and rheumatoid arthritis. 15, 16 The oral bioavailability, safety profile, and low cost of HCQ make it a suitable candidate to test the concept of autophagy inhibition in cancer clinical trials. 17 Herein we report a phase 1/2 prospective clinical trial, in which preoperative autophagy inhibition with HCQ in combination with gemcitabine was evaluated as a novel treatment strategy in PDA.
METHODS

Patient Population
Before initiation of the study, institutional review board approval was obtained from the University of Pittsburgh (PRO10010028) and the trial was registered with the National Cancer Institute (NCI; NCT01128296). All patients signed informed consent. Study eligibility was limited to those patients with biopsy-proven PDA predicted to have limited survival advantage from surgical resection based on a previously published study from our institution. 18 This model defined patients as high risk for inability to achieve an R0 resection if they had evidence of vascular involvement by computed tomographic scan, were found to have stage 2B or higher disease on endoscopic ultrasound, and had primary tumor C2.6 cm on endoscopic ultrasound.
Trial Design
This was a phase 1/2 prospective clinical trial evaluating preoperative gemcitabine plus HCQ. Two doses of fixeddose gemcitabine (1500 mg/m 2 ) were administered (study days 3 and 17) in combination with oral HCQ taken for 31 consecutive days until the day of surgery. A maximum dose of 1200 mg/day of HCQ was established on the basis of prior pharmacologic studies. 15 A Storer design was utilized to escalate the HCQ dose from 200 to 1200 mg/day. 19 
Study Outcomes
The primary outcomes were safety and tolerability. Toxicity was graded by the NCI Common Toxicity Criteria, version 3.0. Patient outcomes were evaluated only if subjects completed more than 80 % of the intended dose of HCQ. Secondary outcomes included clinical response assessed by CA 19-9 response, R0 resection rate, and survival.
Data Analysis
Survival was characterized by Kaplan-Meier estimates with 95 % Borgan-Liestøl confidence regions. Survival functions were compared by means of the log-rank test. The change in CA 19-9 after treatment was evaluated by analysis of covariance on the log-transformed values. A CA 19-9 response was determined on the basis of increase or decrease of the value after treatment. Statistical analyses were performed by R3.1 software.
Additional methods for the clinical trial and correlative studies are listed in the online Supplementary Materials.
RESULTS
Safety of Gemcitabine/HCQ
The safety of autophagy inhibition with HCQ was evaluated in a dose-escalation clinical trial in pancreatic cancer patients. Subjects were at elevated risk for failure to achieve an R0 resection based on criteria previously defined at our institution. 20 Thirty-five (73 %) of 48 patients were enrolled onto the clinical trial (Fig. 1a) . Two patients withdrew study consent before initiation of treatment. One patient was taken off the study protocol after the first dose of gemcitabine after experiencing a cerebrovascular accident judged to be unrelated to study medications. A second patient was removed from the protocol as a result of the development of an allergic rash likely related to gemcitabine treatment, resulting in 31 patients (89 % of the 35 enrolled) completing treatment. Per study protocol, outcomes were reported only for those patients who completed at least 80 % of the HCQ dose (n = 31). Patient demographics and pathologic characteristics are reported in Table 1 . There were no dose-limiting toxicities or treatment delays attributed to HCQ, allowing treatment of one patient at each of the lower dose cohorts and proceeding to the maximum dose of 1200 mg/day for the subsequent 26 patients (Fig. 1b) . Toxicity to treatment is listed in Fig. 1c . A single grade 4 event occurred in a patient with carotid atherosclerosis who developed a cerebrovascular accident, judged to be unrelated to the study drugs.
Twenty-four patients (77 %) required pancreaticoduodenectomy for resection, with 7 patients (23 %) requiring venous resection. Although the study was not powered to detect changes in postoperative morbidity, complications were observed in 58 % of patients. A majority of these were Clavien-Dindo grade I or II (72 %). 21 A grade IV event occurred in a patient who developed a gastric leak after an Appleby procedure, requiring care in the intensive care unit. This patient made a full recovery and is still alive with disease more than 36 months after treatment. There was one perioperative mortality (3 %) in a patient who developed superior mesenteric vein thrombosis as a result of technical complications with the venous anastomosis resulting in ischemic bowel and multisystem organ failure. Pancreatic leak affected four patients (13 %) with two grade A and two grade B leaks. Twenty-four (83 %) of the 29 patients resected were treated with adjuvant gemcitabine. Two patients received postoperative stereotactic body radiotherapy without adjuvant chemotherapy.
Surrogate Oncologic Outcomes of Gemcitabine/HCQ
Twenty-six patients (84 %) had elevated CA 19-9 ([33 U/mL) before initiation of treatment. The CA 19-9 response of each patient is shown in Fig. 2a . Nineteen patients (73 % of those with baseline elevation) demonstrated a CA 19-9 response after completion of preoperative therapy. Thirteen patients (50 %) had a decrease in CA 19-9 of C50 %. Twenty-nine patients (94 %) underwent surgical resection after treatment. Two patients had disease that was deemed unresectable at exploration as a result of liver metastases. Twenty-four patients (77 %) underwent an R0 resection, defined as absence of tumor at the surgical inked margin. R1 resections resulted from a positive retroperitoneal margin (n = 4) and a positive portal vein margin (n = 1). There were no complete pathologic responses. Thirty-five patients were enrolled in the trial (a). Two patients withdrew from the study after signing consent but before receiving treatment to pursue alternative treatment regimens. Two patients were removed from the protocol; one developed a cerebrovascular accident thought to be unrelated to study drugs and another had an allergic rash to gemcitabine. b Storer up and down design and dose escalation schema was used to enable rapid dose escalation of HCQ in individual patients. There were no dose-limiting toxicities to treatment, allowing a single patient to be treated at each of the lower dose cohorts, resulting in 26 patients receiving the maximum tolerated dose. 
Comparison to Previous Institutional Cohort
To put these results into perspective, outcomes were compared to those from the previously established cohort of patients at our institution that defined eligibility for this trial. 18 Demographics and criteria were not different between patients from the prior series and the current trial (Supplementary Table 1 ). The resection rate for patients treated with gemcitabine/HCQ was 94 % compared to 52 % in the prior series (p \ 0.001) with an R0 resection achieved in 77 % versus only 34 % (p \ 0.01). Treatment with gemcitabine/HCQ resulted in improved overall survival compared to the prior cohort (Supplementary Fig. 1 ; 34.83 vs. 12.27 months, p = 0.03).
Correlative Studies
Peripheral blood samples and the resected pancreatic specimen were evaluated for autophagic markers (Supplementary Tables 2, 3) . Peripheral blood mononuclear cells (PBMCs) were collected from whole blood of 17 patients before and after treatment. PBMCs were stained for the autophagic marker LC3-II (Fig. 3a) . Sixty-five percent of patients (11 of 17) had an increase in LC3-II staining with treatment, consistent with autophagy inhibition. Patients who had [51 % increase in their LC3-II staining were classified as having a response to HCQ. Those with HCQ response had improved disease-free survival (15.03 vs. 6.9 months, p = 0.05) and overall survival (34.83 months vs. 10.83, p \ 0.05) compared to patients who had minimal LC3-II response (Fig. 3b, c ). There were trends toward those with HCQ response having decreases in CA 19-9 that did not reach statistical significance. There was no correlation between autophagy markers evaluated in the resected tumor and outcomes, including CA 19-9 response, resection rate, or survival. p53 status was evaluated by immunohistochemical staining of the resected tumor, as outlined in the methods in the online Supplementary Materials. Of the 24 patients assessed, 20 had biologic alteration in p53 (81 %), which was defined either as positive staining in [50 % of tumor cell nuclei (Fig. 4a ) or total absence of nuclear staining (Fig. 4b) . These alterations have been associated with p53 mutation.
23 p53 status did not influence CA 19-9 response (100 vs. 67 %, p = 0.53), ability to achieve an R0 resection (75 vs. 80 %, p = 1.0), or survival (Fig. 4d, e) .
DISCUSSION
Despite recent advances in developing more effective chemotherapeutic regimens, pancreatic cancer remains highly lethal. Inhibition of autophagy represents a novel treatment strategy in pancreatic cancer at a time when new solutions are desperately needed. 8, 14, 24, 25 In this phase 1/2 clinical trial, we established that preoperative treatment with the autophagy inhibitor HCQ in combination with chemotherapy is safe and tolerable.
Early biomarker responses in this trial were greater than what would be expected with a single cycle of gemcitabine. Seventy-three percent of patients with elevated baseline CA 19-9 had a CA 19-9 response, with 50 % of patients demonstrating a reduction of C50 %. Hammad et al. evaluated CA 19-9 response after treatment with one cycle of gemcitabine, resulting in only 25 % of patients demonstrating a decrease in CA 19-9 of C50 %. 26 Moreover, patients who had a decrease in CA 19-9 with treatment had improvements in disease-free and overall survival, suggesting that the study regimen translated into meaningful improvement in oncologic outcomes. This may not be surprising, as early administration of effective chemotherapy has been suggested to be the single most important factor in improved survival in pancreatic cancer. 27 Thus, this surrogate marker of clinical response is encouraging, Data are reported as mean ± SD, median (range), or n (%) especially after only a single cycle of gemcitabine and 30 days of autophagy inhibition. 28, 29 Greater responses may be demonstrated with longer duration of treatment.
The ability to achieve margin-negative R0 resection in PDA is closely linked to survival. 30 We previously defined a population at high risk for a nontherapeutic operation (unresectable disease or an R1 resection). 18 In this cohort of patients from our own institution who received no preoperative treatment, we demonstrated a resection rate of 53 % and an R0 resection rate of 33 % with an overall survival of 12.27 months. Patients meeting the same highrisk criteria defined the eligibility for the current study. The current study demonstrates improvement in surgical resectability and R0 resection rate, suggesting that this regimen is having significant biologic impact. Although the trial was not designed nor powered to analyze survival differences, we did observe an improvement in overall survival after treatment with gemcitabine/HCQ compared to the historical cohort. This improvement may be confounded by introduction of FOLFIRINOX and gemcitabine/nab-paclitaxel, which was utilized as treatment of metastatic disease in some subjects in this cohort but not the historical studies. However, given the observed differences in survival in those with CA 19-9 response in this trial, we cannot discount the notion that the brief, early introduction of an effective chemotherapy regimen played a role in improving survival. Clearly, these results must be interpreted with some caution, as this phase 1/2 trial design lacks a prospective control group for direct outcome comparison. The comparison to a historical cohort has several limitations that limit conclusions that may be drawn regarding the efficacy of the treatment and serves to put our data into perspective rather than permit direct comparison. Linking the observed clinical outcomes to autophagy inhibition requires correlation with markers of autophagy. HCQ functions as a late inhibitor of autophagy by blocking acidification of the lysosome. As a consequence, autophagosomes accumulate, resulting in an increase of LC3-II when autophagy is inhibited. 31 Recently, an increase in greater than 50 % in LC3-II in peripheral blood has been suggested to be a marker of successful autophagy inhibition with HCQ in a murine model and human subjects. 32 In our study, we measured the change in LC3-II expression in PBMCs before and after treatment. Patients with more than 51 % increase in LC3-II had significantly better disease-free and overall survival, suggesting that autophagy inhibition played a role in observed clinical outcomes. Evaluation of PBMCs allowed for pre-and posttreatment comparisons. Unfortunately, similar studies were not possible in the resected pancreatic tumor; as we have not yet validated autophagy measures in cell blocks obtained by fine needle aspiration compared to paraffin-embedded surgical specimens. All surgically resected specimens were evaluated for autophagic markers, and there were no significant outcome correlations. It may be that the change from baseline autophagic levels is more predictive than measurement of autophagy at a single time point after treatment. Identifying patients with disease most likely to respond to autophagy inhibition is an important goal. Although no assays to identify these patients are currently available, this is an area of ongoing investigation in our laboratory.
Recently, p53 status has been implicated in determining the role of autophagy in preclinical murine models. 33 Rosenfeldt et al. found that blocking autophagy prevented pancreatic carcinogenesis in mice with an oncogenic Kras allele. However, in Kras mutant/p53 knockout mice, inhibition of autophagy actually promoted tumor growth. This work has garnered substantial attention throughout the biomedical community, given several ongoing trials utilizing autophagy inhibition in various malignancies. 34, 35 The role of autophagy in established tumors may be much different than that observed during carcinogenesis. The murine models evaluated by Rosenfeldt et al. only examined the impact of autophagy inhibition during carcinogenesis. Additionally, these studies did not use chemotherapy in combination with autophagy inhibitors, which is known to further promote the survival pathway of autophagy. [36] [37] [38] We and others have not observed promotion of tumor growth either in vitro or in vivo with autophagy inhibition. 5, 7, 8, 39, 40 In the current clinical study, there was no evidence to conclude that clinical outcomes after autophagy inhibition were related to p53 status. However, because only 19 % of the patients assessed had no apparent p53 alterations, this study was underpowered to definitively rule out the contribution of p53 mutational status. 41 It should be noted that although immunohistochemical alterations in p53 expression have been associated with p53 mutation, a full genetic analysis was not performed for the current study.
In conclusion, preoperative autophagy inhibition with HCQ in PDA represents a novel treatment strategy that is safe with encouraging clinical outcomes compared to historical controls. Peripheral blood measurement of autophagy inhibition correlated with survival. p53 status did not appear to be important in defining responses. On the basis of these results, we are actively accruing subjects to an NCI-supported (R01CA181450) randomized trial of neoadjuvant gemcitabine/nab-paclitaxel with and without HCQ (NCT01978184) to better assess the true contribution of autophagy inhibition in the setting of effective chemotherapy. 
